DBV Technologies | DBVT - 净收入



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 727.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


净收入 更改 日
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amarin USD -1.22M 6.51M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
DBV Technologies USD -33.16M 8.71M 2025-09
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Galectin Therapeutics USD -12.37M 880K 2024-06
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Incyte USD 303.33M 4.05M 2026-03
Insmed USD -163.56M 164.92M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
PTC Therapeutics USD -2.81M 132.16M 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03